Skip to main content Skip to navigation

Preserve the cellular transcriptome and proteome

Generating high-quality single-cell data requires samples with high cell viability and minimum to no alteration of their true biological state. This is especially challenging for single-cell workflows, which often require long processing and handling times. Further complicating the above are studies that require shipping or transferring of samples across different sites and locations. Keeping these needs in mind, a novel cell preservation solution was developed that works across a variety of single-cell applications including flow cytometry, RNA-seq, CITE-seq and qPCR.

 

This webinar will showcase two sets of data powered by this novel cell preservation solution. First, learn how it enabled researchers to explore the tumor microenvironment (TME) and its influence on immunomodulatory agents. A novel approach to examine immune responses in the TME with small tumor samples will be presented. This approach has now helped uncover the balance of PD-1 expression between tumor-infiltrating effector cells and regulatory T (Treg) cells as a biomarker for evaluating the effects of PD-1/PD-L1 blockade immunotherapy. 


The second set of data will walk you through a step-by-step approach for conducting single-cell multiomics studies to generate high-quality data with preserved samples. Learn how to preserve and ship your samples for up to 72 hours at 4°C and still generate RNA-seq, CITE-seq and TCR/BCR single-cell data with confidence. 


Learn how to:

  • Preserve and ship cells and tissues for multisite studies
  • Employ cell preservation technologies critical to discovery studies using tumor samples
  • Use a single preservation solution to support flow cytometry, RNA-seq and CITE-seq research

 

Speakers

       

Hiroyoshi Nishikawa, MD, PhD, Division of Cancer Immunology, Research Institute National Cancer Center Japan


Hiroyoshi Nishikawa
has continuously studied the role of immunosuppressive mechanisms, particularly regulatory T cells in tumor immunity. He is involved in both basic research of immune regulation, particularly immune tolerance induced by regulatory T cells, and translational research developing novel cancer immunotherapies targeting regulatory T cells. In 2023, Dr. Nishikawa was honored as one of the Highly Cited Researchers 2023 by Clarivate Analytics fourth consecutive year, following his recognition from 2020. He continues to be at the forefront of cancer immunology research.

 

     

  

Cynthia Sakofsky, PhD, Staff Scientist, BD Bioscience
 

Cynthia Sakofsky has over 15 years of research experience working in the field of genomics, which she now brings to the advancement of single-cell biotechnology. Cynthia is currently a staff scientist at BD Biosciences, where she drives novel application and technology development projects within the single-cell multiomics platform. She earned her PhD in Molecular Genetics at the University of Cincinnati and continued her postdoctoral research at the National Institutes of Health (NIH). 

Watch the Webinar On Demand


*Required fields

   

   

For Research Use Only. Not for use in diagnostic or therapeutic procedures.